17 completed. 17 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 17 |
| Phase 1 | 5 | Completed 5 |
Follow Chronic Lymphocytic Leukemia (CLL): new trials by email Literature Review of Chronic Lymphocytic Leukemia (CLL) trials Research Report on Chronic Lymphocytic Leukemia (CLL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Venetoclax, Ibrutinib, Obinutuzumab - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Completed | AbbVie | 20 | 2021-11-08 | 2026-10-21 |
| Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma Acalabrutinib, Rituximab - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | Phase 2 | Completed | University of Rochester | 39 | 2019-03-25 | 2024-09-26 |
| Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I) Zoster Vaccine Recombinant, Adjuvanted - Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 116 | 2018-12-07 | 2023-08-04 |
| HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Fludarabine, Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5, Total Body Irradiation (TBI) 200cGy on Day -1 - Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Completed | Center for International Blood and Marrow Transplant Research | 80 | 2016-12-01 | 2025-08-06 |
| Study Evaluating Venetoclax in Subjects With Hematological Malignancies azacitadine, venetoclax, rituximab / IDEC-C2B8 - Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM) | Phase 1 / Phase 2 | Completed | AbbVie | 38 | 2014-09-22 | 2021-08-02 |
| IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT ALT-803 - Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) | Phase 1 / Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 33 | 2013-11-11 | 2020-08-12 |
| Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Ublituximab - Non-Hodgkins Lymphoma, B-cell Lymphoma | Phase 1 / Phase 2 | Completed | TG Therapeutics, Inc. | 39 | 2012-07-19 | 2022-11-21 |
| Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies POL6326, Leukapheresis, PBSC Transplant - Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Polyphor Ltd. | 38 | 2012-04-01 | 2016-02-26 |
| Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) Ofatumumab, Bendamustine - Chronic Lymphocytic Leukemia (CLL), Leukaemia, Lymphocytic, Chronic | Phase 2 | Completed | Novartis Pharmaceuticals | 99 | 2012-03-01 | 2017-01-19 |
| Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide - Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Completed | Hackensack Meridian Health | 21 | 2012-02-22 | 2026-04-03 |
| A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Rituximab, Bendamustine, MEDI-551 - Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Completed | MedImmune LLC | 183 | 2012-02-07 | 2017-05-31 |
| An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) Ofatumumab with GSK2110183 - Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Completed | University Health Network, Toronto | 28 | 2012-02-01 | 2019-09-24 |
| Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL) auranofin - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma | Phase 2 | Completed | University of Kansas Medical Center | 15 | 2011-09-01 | 2016-01-18 |
| Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia TRU-016 and bendamustine, Bendamustine, 15 mg/kg TRU-016 and bendamustine - Chronic Lymphocytic Leukemia (CLL) | Phase 1 / Phase 2 | Completed | Aptevo Therapeutics | 79 | 2010-09-01 | 2021-06-10 |
| Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL) forodesine HCl - Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Completed | BioCryst Pharmaceuticals | 23 | 2008-03-01 | 2012-01-23 |
| Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Lenalidomide - Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma | Phase 2 | Completed | Georg Aue, M.D. | 33 | 2007-02-01 | 2014-01-13 |
| Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia Alemtuzumab, Fludarabine, Cytoxan - Leukemia, B-cell Leukemia | Phase 2 | Completed | Steven E. Coutre | 25 | 2004-07-01 | 2014-10-06 |
Leukemia, Lymphocytic, Chronic, B-Cell (17) · Lymphoma, Non-Hodgkin (4) · Recurrence (4) · Leukemia, Myeloid, Acute (3) · Myelodysplastic Syndromes (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Leukemia (2) · Leukemia, B-Cell (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Lymphoma (2) · Multiple Myeloma (2) · Herpes Simplex (1) · Herpes Zoster (1) · Hodgkin Disease (1) · Leukemia, Biphenotypic, Acute (1)
Chronic Disease (17) · Disease Attributes (17) · Hematologic Diseases (17) · Hemic and Lymphatic Diseases (17) · Immune System Diseases (17) · Immunoproliferative Disorders (17) · Neoplasms by Histologic Type (17) · Pathologic Processes (17) · Pathological Conditions, Signs and Symptoms (17) · Leukemia, Lymphoid (16) · Lymphatic Diseases (16) · Lymphoproliferative Disorders (16) · Neoplasms (16) · Leukemia (15) · Leukemia, B-Cell (15)
Rituximab (4) · Bendamustine Hydrochloride (3) · Cyclophosphamide (3) · fludarabine (3) · Lenalidomide (2) · fludarabine phosphate (2) · ofatumumab (2) · venetoclax (2) · ALT-803 (1) · Alemtuzumab (1) · Auranofin (1) · Busulfan (1) · Filgrastim (1) · GSK2110183 (1) · Granulocyte Colony-Stimulating Factor (1)
AbbVie (2) · Aptevo Therapeutics (1) · BioCryst Pharmaceuticals (1) · Center for International Blood and Marrow Transplant Research (1) · Georg Aue, M.D. (1) · Hackensack Meridian Health (1) · Masonic Cancer Center, University of Minnesota (1) · MedImmune LLC (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Novartis Pharmaceuticals (1) · Polyphor Ltd. (1) · Steven E. Coutre (1) · TG Therapeutics, Inc. (1) · University Health Network, Toronto (1) · University of Kansas Medical Center (1)
United States (14) · Poland (3) · Belgium (2) · Canada (2) · Germany (2) · Italy (2) · Japan (2) · Spain (2) · Australia (1) · Austria (1) · Czechia (1) · France (1) · Greece (1) · Israel (1) · Russia (1)
Andre Goy, MD (1) · Asher Chanan-Khan, MD (1) · Bronwen E. Shaw, MD, PhD (1) · Christine Chen, MD (1) · Christopher MT Pleyer, M.D. (1) · Daniel Couriel, M.D. (1) · Georg Aue, MD (1) · Jeffrey S. Miller, MD (1) · Paul Barr (1) · Scott Stromatt, MD (1)
PMID 21812019, PMID 27222473, PMID 29463563, PMID 33259596, PMID 33905264, PMID 35157769, PMID 35254001, PMID 36689726